Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

June 24, 2010

New York Times puts Avid’s Technology Front and Center

Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights…

Posted by James A. Datin

May 21, 2010

Diagnostic Imaging Continues to Garner Investor Interest

On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…

Posted by James A. Datin

April 15, 2010

Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18

Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…

Posted by Peter J. Boni

March 31, 2010

Avid Radiopharmaceuticals Making Strides Toward Clinical Trial Milestone

I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…

Posted by Peter J. Boni

March 11, 2010

Fourth Quarter and Fiscal 2009 Financial Disclosures Articulate 2010 Opportunities and Objectives

In our report for the period ended Dec. 31, 2009 that was released this morning, we updated investors on the significant progress achieved by Safeguard…

Posted by Peter J. Boni

January 21, 2010

Avid Radiopharmaceuticals Presents at J.P. Morgan Investor Conference

Safeguard Scientifics’ partner company Avid Radiopharmaceuticals was invited to present its technology and growth strategy at the prestigious J.P. Morgan 28th Annual Healthcare Conference in…

Posted by James A. Datin

Content